Stocks and Investing
Stocks and Investing
Tue, July 11, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Terence Flynn Reiterated (ABBV) at Buy and Held Target at $182 on, Jul 11th, 2023
Terence Flynn of Morgan Stanley, Reiterated "AbbVie Inc." (ABBV) at Buy and Held Target at $182 on, Jul 11th, 2023.
Terence has made no other calls on ABBV in the last 4 months.
There are 4 other peers that have a rating on ABBV. Out of the 4 peers that are also analyzing ABBV, 2 agree with Terence's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Carter Gould of "Barclays" Maintained at Hold with Increased Target to $160 on, Thursday, April 13th, 2023
- Jasper Hellweg of "Argus Research" Downgraded from Strong Buy to Hold on, Wednesday, April 5th, 2023
These are the ratings of the 2 analyists that currently disagree with Terence
- Mohit Bansal of "Wells Fargo" Maintained at Buy with Decreased Target to $195 on, Friday, April 28th, 2023
- Vamil Divan of "Guggenheim" Maintained at Strong Buy with Decreased Target to $171 on, Friday, April 28th, 2023
Contributing Sources